SCALOP-2

NCT02024009 📎

Regimen

Experimental
Five-arm comparison with 2x2 factorial: standard (50.4 Gy) vs high-dose (60 Gy) CRT, each ± nelfinavir (HIV protease inhibitor at MTD 1250 mg BID) as radiosensitizer.
Control
Standard 50.4 Gy CRT + capecitabine (no nelfinavir) as reference arm.

Population

Locally advanced PDAC, stable/responding after 4 cycles gemcitabine + nab-paclitaxel induction, UK multicenter.

Key finding

SCALOP-2 showed neither dose-escalated chemoradiation (60 Gy vs 50.4 Gy) nor the addition of nelfinavir improves outcomes in locally advanced PDAC after induction gem+nab-pac. Both primary endpoints failed. Reinforces LAP07's message that consolidative chemoRT intensification yields no OS gain in LA-PDAC.

Source: PMID 39059185

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.65)